Welcome to our dedicated page for Pressure Bio news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on Pressure Bio stock.
Pressure BioSciences Inc. (PBIO) is a biotechnology innovator specializing in pressure cycling technology (PCT) and UltraShear nanoemulsion platforms. This page provides investors and industry professionals with a comprehensive collection of official announcements, financial disclosures, and scientific developments related to the company's patented methods for enhancing bio-molecular interactions.
Access timely updates on PBIO's advancements in pharmaceutical formulation, nutraceutical delivery systems, and strategic partnerships. Key content includes earnings reports, technology licensing agreements, clinical application progress, and regulatory milestones. All materials are sourced directly from company filings and verified industry channels.
Regularly refreshed content ensures stakeholders maintain current awareness of PBIO's work in creating stable nanoemulsions for improved drug bioavailability. Bookmark this page for efficient tracking of the company's progress in pressure-based biomolecule manipulation techniques and their commercial applications.
Pressure BioSciences (OTCQB:PBIO) announced a partnership with Dr. Denese SkinScience to develop new skincare products utilizing patented UST nanoemulsion technology. This collaboration aims to enhance the delivery of nutrients like retinol and lipid-soluble Vitamin C, and to launch a hair regrowth product line by Christmas 2023. The first products leveraging this technology are expected to generate millions in revenue for PBIO. Dr. Adrienne Denese emphasized the urgent demand for effective hair loss solutions, particularly among women.
Pressure BioSciences, Inc. (PBIO) announced their participation in a webinar on October 13, 2022, focusing on a new generation of skincare products developed using their Ultra Shear Technology (UST). The event will feature Dr. Adrienne Denese, a skincare pioneer with significant sales success. The company's UST platform enhances the absorption and stability of active ingredients in skincare, promising improved therapeutic benefits. PBIO anticipates hundreds of thousands in incremental revenue in Q4 2022, potentially reaching millions in FY 2023. This partnership positions PBIO for growth in the cosmeceuticals market.
Pressure BioSciences (OTCQB:PBIO) announced plans for multiple shipments of nanoemulsified CBD products, anticipating incremental revenue in the hundreds of thousands for Q4 2022 and in the millions for FY 2023. The company highlighted its participation in the Emerging Growth Investor Conference, where CEO Richard Schumacher will present the launch of the Ultra Shear Technology (UST) nanoemulsification platform. Four agreements for UST-processed CBD products could generate over $5 million in revenue for 2023. The company expects Q4 revenue from pilot manufacturing to exceed $250,000.
Pressure BioSciences (OTCQB:PBIO) showcased key findings at the Conference of Food Engineering 2022, validating its Ultra Shear Technology (UST) for enhancing food safety and stability. Presentations emphasized UST's scalability for commercial applications in multi-billion-dollar markets, particularly in plant-based beverages. Validation studies demonstrated UST's effectiveness in reducing harmful bacteria and optimizing product characteristics. The company anticipates launching UST-processed products in Q4 2022, aiming to facilitate partnerships across various industries, including food, nutraceuticals, and pharmaceuticals.
Pressure BioSciences (OTCQB:PBIO) is shifting its primary focus to the Ultra Shear Technology (UST) platform, anticipating at least ten tolling contracts to generate $1 million or more in revenue each. The company expects to earn over $5 million from its current contracts in FY 2023. Recent partnerships include production and distribution agreements for nanoemulsified CBD products and a collaboration with Dr. Denese SkinScience for cosmeceuticals. CEO Richard T. Schumacher will present at the H.C. Wainwright Annual Global Investor Conference on September 13, 2022.
Pressure BioSciences, Inc. (OTCQB:PBIO) has announced a two-year Collaborative Research and Development Agreement with Dr. Adrienne Denese, a prominent figure in the skincare industry. The partnership aims to utilize PBI’s Ultra Shear Technology™ (UST) to enhance and develop new skincare products, focusing on improved absorption and therapeutic benefits. Dr. Denese's products have achieved over $560 million in sales through QVC. The collaboration seeks to drive multi-million dollar revenue growth and capitalize on the estimated $130 billion cosmeceuticals market.
Pressure BioSciences, Inc. (PBIO) has partnered with Canopy CBD Farms to commercialize a new hemp-derived CBD product, leveraging PBIO's patented Ultra Shear Technology to create effective nanoemulsions. The agreement projects nearly $6 million in sales within the first year, with PBIO estimated to capture $2 million of this revenue. The partnership aims to meet rising demand for USDA-compliant CBD products. Future revenues are anticipated to accelerate into 2023 with broader distribution plans.
Pressure BioSciences, Inc. (OTCQB:PBIO) will host a teleconference on August 18, 2022, at 4:30 PM ET, to discuss its Second Quarter 2022 financial results and business updates. Participants can join live via telephone or listen to a replay starting from August 19, 2022. The company specializes in pressure-based solutions for life sciences, utilizing patented technologies such as pressure cycling technology and Ultra Shear Technology, which have significant applications in biopharma and food preservation.
Pressure BioSciences (OTCQB: PBIO) announced that its South Easton, MA facility received state approval for manufacturing hemp-derived CBD nanoemulsions in partnership with Canopy CBD Farms. This milestone enables PBI to leverage its patented Ultra Shear Technology to produce water-soluble CBD products aimed at various markets, including nutraceuticals and cosmetics. The approval comes amid growing demand in a global CBD market projected to reach $16.6 billion by 2027. PBI's innovative nanoemulsions are designed for improved absorption and dosing reliability.
Pressure BioSciences, Inc. (OTCQB:PBIO) highlighted its participation in the San Francisco and Chicago Cannabis Drinks Expos, generating over 60 strong leads for contracts in the cannabis beverage sector. The company's Ultra Shear Technology platform addresses critical challenges in cannabis dosing. Following positive feedback, PBI has increased its forecast, expecting to secure 12 UST contracts by the end of 2022, each potentially adding $1M+ to annual revenue. This reflects a significant expansion in the $2 billion cannabis beverage market.
FAQ
What is the current stock price of Pressure Bio (PBIO)?
What is the market cap of Pressure Bio (PBIO)?
